Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-11048-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Cheng Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyrimidines, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Development Plan for Youth Innovation Team in Higher School of Shandong Province, Weifang Science and Technology Development Plan Project.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often linked to overexpression or abnormal activation of the epidermal growth factor receptor (EGFR). The issue of developing resistance to third-generation EGFR kinase inhibitors, such as osimertinib, underscores the urgent need for new therapies to overcome this resistance. Our findings revealed that compound A8 exhibits 88.01% kinase inhibition efficacy against the EGFRL858R/T790M mutation at a concentration of 0.1 μM, with an IC50 value of 5.0 nM. Moreover, its selectivity for this double mutation is 29.5, surpassing that of osimertinib. Most notably, A8 demonstrates an inhibitory activity of 2.9 nM against the EGFRL858R/T790M/C797S triple mutation, outperforming the benchmark drug osimertinib. Furthermore, compound A8 has demonstrated strong antiproliferative effects against H1975 cells, and its activity was better than osimertinib. The mechanism by which compound A8 operates as a selective EGFRL858R/T790M inhibitor was confirmed through a series of cell migration, apoptosis, and cell cycle assays. This lays the foundation for the development of a new structural type of EGFR kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China.
- School of Basic Medical Sciences, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China.
- School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China. lynlyna@163.com.
- School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong, People's Republic of China. jinxinghu2013@sdsmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Development Plan for Youth Innovation Team in Higher School of Shandong Province
- Weifang Science and Technology Development Plan Project
- Weifang Science and Technology Development Plan Project for Medicine
- Shandong Provincial Natural Science Foundation
- Shandong Students innovation and entrepreneurship training program
Zitieren
APA
Zhang, C., Huo, Y., Fu, J., Liu, Y., Zhou, Q., Hou, M., Duan, X., Lv, Y., & Hu, J. (2025). Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-024-11048-8
Vancouver
Zhang C, Huo Y, Fu J, Liu Y, Zhou Q, Hou M, et al. Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors. Molecular Diversity. 2025. doi:10.1007/s11030-024-11048-8
BibTeX
@article{Zhang2025,
author = {Zhang, Cheng and Huo, Yiwen and Fu, Jianfang and Liu, Yue and Zhou, Qinjiang and Hou, Mingyue and Duan, Xiaoxuan and Lv, Yanna and Hu, Jinxing},
title = {Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-11048-8}
}
EUVIMED